KLOW Research: KPV + GHK-Cu + BPC-157 + TB-500 Blend
KLOW combines four recovery-focused peptides into one vial. This page breaks down the literature behind each component, the convenience of a blended format, and the dosing trade-offs researchers should understand.
Mechanism of action
KLOW is a fixed-ratio combination of four distinct research peptides: KPV, GHK-Cu, BPC-157 and TB-500. Each component targets a different part of the tissue-repair and inflammation-control cascade, and the blend is studied precisely because the four mechanisms are thought to complement one another.
KPV (Lysine-Proline-Valine) is a tripeptide fragment cleaved from the C-terminus of alpha-MSH. Research focuses on its ability to dampen NF-κB-driven inflammatory signalling inside cells, particularly in epithelial and mucosal barrier models.
GHK-Cu is a copper-binding tripeptide found naturally in human plasma. Literature tracks its effects on collagen, elastin and glycosaminoglycan production, plus antioxidant gene expression in fibroblasts and skin-ageing models. The copper complex is also what gives a reconstituted KLOW vial its characteristic blue colour.
BPC-157 is a 15-amino-acid synthetic peptide modelled on a protective sequence from human gastric juice. The research literature most often ties it to angiogenesis via VEGFR2 signalling, with studies in tendon, muscle and gastrointestinal injury models.
TB-500 is a synthetic fragment of Thymosin Beta-4. The proposed role is actin-cytoskeleton regulation: directing repair-cell migration, adhesion and structural organisation at injury sites. In the blend it is often framed as the 'logistics' component that helps recruited cells actually remodel tissue.
The studies
There are no large clinical trials of the KLOW blend itself. The evidence base is the individual component literature, summarised below by compound so the mechanism and model for each one is clear.
KPV — inflammation modulation
KPV attenuates colitis and intestinal inflammation in rodent models
Whether the tripeptide KPV reduces intestinal inflammation and preserves mucosal barrier function in inflammatory bowel disease models.
Mouse colitis models · oral or systemic KPV · histology, cytokine profiling and barrier-permeability endpoints
- Reduced
- NF-κB activity
- Attenuated
- Intestinal inflammation
- Preserved
- Mucosal barrier
- KPV appears to work intracellularly on inflammatory gene expression rather than through classical melanocortin receptor pathways.
- The colitis models are pre-clinical; translation to human intestinal disease has not been established.
GHK-Cu — collagen and dermal repair
GHK-Cu gene-expression and skin-ageing studies
How GHK-Cu influences gene expression related to wound healing, collagen synthesis and antioxidant defence in human skin and fibroblast models.
Human fibroblast cultures and human skin biopsy models · gene-expression profiling and histological collagen scoring
- Up-regulated
- Collagen production
- Increased
- Elastin and glycosaminoglycans
- Activated
- Antioxidant genes
- GHK-Cu is one of the better-studied topical and injectable peptides for dermal repair, with both cell-culture and small human data.
- Most anti-ageing evidence is cosmetic/dermatological; systemic recovery applications are less well characterised.
BPC-157 — angiogenesis and tissue repair
BPC-157 accelerates tendon fibroblast outgrowth and migration
The cellular mechanism behind BPC-157's tendon-healing observations in animal models.
Cultured rat Achilles tendon fibroblasts · outgrowth, migration and survival under oxidative stress
- Accelerated
- Fibroblast outgrowth
- Increased
- Cell migration
- Improved
- Oxidative-stress survival
- Provides a plausible in-vitro mechanism for the tendon-repair findings seen in rodents.
- Cell-culture results do not prove clinical efficacy; human tendon data are extremely limited.
TB-500 — actin and cell migration
Thymosin Beta-4 and wound-repair mechanisms
How Thymosin Beta-4 regulates actin dynamics, cell migration and wound healing across tissue types.
Review of pre-clinical wound, corneal and cardiac injury models · actin-cytoskeleton and cell-migration endpoints
- Enhanced
- Cell migration
- Modulated
- Actin polymerisation
- Accelerated in models
- Wound closure
- TB-500 is studied as a fragment of Thymosin Beta-4, a protein central to actin organisation and cell movement.
- The wound-healing data are predominantly animal and cell-based; robust human trials are lacking.
Storage & handling
KLOW is supplied as a lyophilised powder blend. Store sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute slowly with bacteriostatic water added down the inner wall of the vial; swirl gently until dissolved. Avoid shaking.
The copper in GHK-Cu gives the reconstituted liquid a vivid blue colour. This is expected and does not indicate contamination.
Keep reconstituted solution at 2-8 °C and use within your lab's validated stability window. Minimise freeze-thaw cycles.
Blend convenience vs. individual dosing
A fixed-ratio blend reduces the number of injections, but it locks the relative doses of all four peptides together. That matters because each component has a different side-effect and dose-response profile.
| Approach | Convenience | Dosing flexibility |
|---|---|---|
| KLOW blend | One vial, one reconstitution, fewer injections per day. | Fixed ratio — raising one peptide raises all four. GHK-Cu stinging or oedema may limit how far the total dose can be pushed. |
| Individual peptides | More vials, more injections, more reconstitution steps. | Each peptide can be titrated independently based on the research question and observed response. |
KLOW research context
A few practical points help interpret the blend literature accurately.
Fixed ratios limit independent dose adjustment
A typical 80 mg vial might contain roughly 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV. Researchers who want to increase BPC-157 for a tendon model must also increase GHK-Cu, which can intensify injection-site reactions.
GHK-Cu can cause localised reactions
GHK-Cu is generally well tolerated, but higher concentrations are commonly associated with transient stinging, redness and local fluid retention (oedema) at the injection site.
No large human trials of the blend itself
KLOW is a compounding blend. The evidence base is the individual component literature plus practitioner and preclinical compounding experience. It is not an FDA- or SAHPRA-approved medicine.
Research use only
Material supplied here is strictly for laboratory research and is not for human or veterinary use.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.